A phase 2, open-label, single-arm Study of ADXS-31164 [ADXS-cHER2] in patients with HER2-expressing recurrent, completely resected osteosarcoma.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs ADXS 31164 (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions
- 13 Jun 2017 According to an Advaxis media release, data from this trial presented at annual Investor & Analyst Day.
- 13 Jun 2017 According to an Advaxis media release, this study is being conducted in collaboration with the Childrens Oncology Group.
- 09 Jan 2017 According to an Advaxis media release, the company plans to initiate this trial in 2017.